Evidence map›Paper›PMID 36612263›Full record

ArticleCancers2022

The Prognostic-Based Approach in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors (PitNET): Tertiary Reference Center, Single Senior Surgeon, and Long-Term Follow-Up.

Abel Ferrés, Luís Reyes, Alberto Di Somma, Thomaz Topczewski, Alejandra Mosteiro, Giulia Guizzardi, Andrea De Rosa, Irene Halperin, Felicia Hanzu, Mireia Mora and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Grading and staging for pituitary neuroendocrine tumors.Brain pathology (Zurich, Switzerland) · 2025
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Abel FerrésDepartment of Neurosurgery, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-0003-3235
Luís ReyesDepartment of Neurosurgery, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-1209-7535
Alberto Di SommaDepartment of Neurosurgery, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Thomaz TopczewskiDepartment of Neurosurgery, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Alejandra MosteiroDepartment of Neurosurgery, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Giulia GuizzardiDepartment of Neurosurgery, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Andrea De RosaDepartment of Neurosurgery, Policlinico Federico II, 80131 Napoli, Italy.
Irene HalperinFaculty of Medicine, University of Barcelona, 08036 Barcelona, Spain.
Felicia HanzuFaculty of Medicine, University of Barcelona, 08036 Barcelona, Spain.
Mireia MoraFaculty of Medicine, University of Barcelona, 08036 Barcelona, Spain.
Isam AlobidFaculty of Medicine, University of Barcelona, 08036 Barcelona, Spain.ORCID 0000-0003-2557-6017
Iban AldecoaFaculty of Medicine, University of Barcelona, 08036 Barcelona, Spain.
Núria BargallóFaculty of Medicine, University of Barcelona, 08036 Barcelona, Spain.
Joaquim EnseñatDepartment of Neurosurgery, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Hospital Clínic de Barcelona · ESFederico II University Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Postoperative deserved outcomes in acromegalic patients are to normalize serum insulin-like growth factor (IGF-1), reduce the tumoral mass effect, improve systemic comorbidities, and reverse metabolic alterations. Pituitary neuroendocrine tumors (PitNET) are characterized to present a heterogeneous behavior, and growth hormone (GH)-secreting PitNET is not an exception. Promptly determining which patients are affected by more aggressive tumors is essential to guide the optimal postoperative decision-making process [prognostic-based approach]. From 2006 to 2019, 394 patients affected by PitNET were intervened via endoscopic endonasal transsphenoidal approach by the same senior surgeon. A total of 44 patients that met the criteria to be diagnosed as acromegalic and were followed up at least for 24 months (median of 66 months (26-156) were included in the present study. Multiple predictive variables [age, gender, preoperative GH and IGF-1 levels, maximal tumor diameter, Hardy's and Knosp's grade, MRI. T2-weighted tumor intensity, cytokeratin expression pattern, and clinicopathological classification] were evaluated through uni- and multivariate statistical analysis. Sparse probability of long-term remission was related to younger age, higher preoperative GH and- or IGF-1, group 2b of the clinicopathological classification, and sparsely granulated cytokeratin expression pattern. Augmented recurrence risk was related to elevated preoperative GH levels, tumor MRI T2-weighted hyperintensity, and sparsely granulated cytokeratin expression pattern. Finally, elevated risk for reintervention was related to group 2b of the clinicopathological classification, Knosp's grade IV, and tumor MRI T2-weighted hyperintensity. In this study, the authors determined younger age, higher preoperative GH and- or IGF-1 levels, group 2b of the clinicopathological classification, Knosp's grade IV, MRI T2-weighted tumor hyperintensity and sparsely granulated cytokeratin expression pattern are related to worse postoperative outcomes in long-term follow-up patients affected with GH-secreting PitNET.

Indexed as

acromegalyendoscopic endonasal approachlong-term follow-uppituitary glandpituitary neuroendoendocrine tumorprognostic factors

Identifiers

PMID36612263
PMCPMC9818833
OpenAlexW4313473015

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.